Breaking News Instant updates and real-time market news.

GEMP

Gemphire Therapeutics

$7.33

-0.2 (-2.66%)

16:11
08/06/18
08/06
16:11
08/06/18
16:11

Gemphire amends loan agreement with SVB to provide additional flexibility

On July 31, Gemphire amended its loan agreement with Silicon Valley Bank to provide additional flexibility to the Company. The original agreement established a term loan facility of up to $15m in aggregate principal amount to be funded in up to three tranches. The company received the first two tranches, $10M in aggregate, in July 2017.Among other provisions, the loan amendment with SVB: the date by which the FDA must lift the 6-month partial clinical hold from July 31 to September 30, 2019 for purposes of the requirement to provide cash security to SVB or prepayment of the loan, which could also be required if the Company's unrestricted cash balance falls below a minimum amount prior to such time.Extends the date that the third tranche of $5 million is available for draw down by the Company to November 30 should the conditions set forth in the amended loan agreement be met by such date. Extends the interest-only monthly payment period from August 1, 2018 to November 1, 2018, which may be subject to further extension if certain conditions set forth in the loan agreement are met.

GEMP Gemphire Therapeutics
$7.33

-0.2 (-2.66%)

12/22/17
ROTH
12/22/17
NO CHANGE
Target $30
ROTH
Buy
Gemphire transition to NASH a value creator, says Roth Capital
Roth Capital analyst Yasmeen Rahimi views Gemphire Therapeutics' transition into non-alcoholic steatohepatitis as an "important shareholder value creator." After the company announced the launch of proof-of-concept Phase 2a trial of gemacabene in eight patients with familial partial lipodystrophy, a rare genetic metabolic condition characterized by abnormal distribution of subcutaneous fat which then leads to NASH, the analyst keeps a Buy rating on Gemphire with a $30 price target.
01/26/18
HCWC
01/26/18
NO CHANGE
Target $28
HCWC
Buy
Gemphire Therapeutics price target raised to $28 from $22 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Gemphire Therapeutics to $28 saying he sees a "catalyst-rich" 2018 for the company. The analyst says his confidence grows in the emerging multiple mechanisms of the compound as the gemcabene pipeline expands. He keeps a Buy rating on Gemphire Therapeutics.
05/16/18
RAJA
05/16/18
INITIATION
Target $22
RAJA
Outperform
Gemphire Therapeutics initiated with an Outperform at Raymond James
Raymond James analyst Laura Chico initiated Gemphire Therapeutics with an Outperform and $22 price target saying its gemcabene offs a potentially differentiated profile in the dyslipidemia space, which should narrow the gap versus peers with successful data.
07/27/18
ROTH
07/27/18
NO CHANGE
Target $40
ROTH
Buy
Gemphire Therapeutics price target raised to $40 from $30 at Roth Capital
Roth Capital analyst Yasmeen Rahimi raised her price target for Gemphire Therapeutics to $40 from $30 based on a positive forecast for the company's lead molecule in the pediatric NASH trial. In a research note to investors, Rahimi projects $415M peak sales for gemcabene for pediatric NASH in the U.S. in 2028 based on assumptions that include ~7.5M children with NAFLD among which 25% progress to NASH of which 12% have advanced NASH, as well as a U.S. launch in 2022 in 4% with peak market penetration of 55%. Rahimi, who has a Buy rating on Gemphire, sees top-line six-month histology results for the 24-week Phase 2a study in eight NASH patients with familial partial lipodystrophy in the fall, which will give clearer and early indications of gemcabene's effects on biopsy.

TODAY'S FREE FLY STORIES

CNI

Canadian National

$87.09

-0.32 (-0.37%)

16:03
03/20/19
03/20
16:03
03/20/19
16:03
Hot Stocks
Canadian National investing approximately $345M into B.C.'s rail infrastructure »

CN said it plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

MU

Micron

$40.17

-0.21 (-0.52%)

16:02
03/20/19
03/20
16:02
03/20/19
16:02
Earnings
Micron reports Q2 EPS $1.71, consensus $1.67 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 28

    May

CBMG

Cellular Biomedicine

$18.34

0.46 (2.57%)

16:02
03/20/19
03/20
16:02
03/20/19
16:02
Syndicate
Cellular Biomedicine files to sell common stock, no amount given »

Cantor Fitzgerald &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WMT

Walmart

$98.65

-1.24 (-1.24%)

, AMZN

Amazon.com

$1,790.05

27.6 (1.57%)

15:56
03/20/19
03/20
15:56
03/20/19
15:56
Periodicals
Walmart's Chief Technology Officer leaving company, Reuters reports »

Walmart (WMT) Chief…

WMT

Walmart

$98.65

-1.24 (-1.24%)

AMZN

Amazon.com

$1,790.05

27.6 (1.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 26

    Mar

  • 04

    Apr

  • 16

    May

SCHW

Charles Schwab

$44.70

-1.05 (-2.30%)

15:55
03/20/19
03/20
15:55
03/20/19
15:55
Options
Charles Schwab put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:55
03/20/19
03/20
15:55
03/20/19
15:55
Conference/Events
William Blair healthcare/biotech analysts to hold a dinner meeting »

Analysts meet with…

APTO

Aptose Biosciences

$2.29

0.15 (7.01%)

15:54
03/20/19
03/20
15:54
03/20/19
15:54
Conference/Events
Aptose Biosciences management to meet with Oppenheimer »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 25

    Mar

JOUT

Johnson Outdoors

$69.11

-0.54 (-0.78%)

15:51
03/20/19
03/20
15:51
03/20/19
15:51
Conference/Events
Johnson Outdoors management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

FB

Facebook

$165.22

3.63 (2.25%)

, SPOT

Spotify

$144.16

2.565 (1.81%)

15:51
03/20/19
03/20
15:51
03/20/19
15:51
On The Fly
#SocialStocks: Facebook downgraded to cap rough week »

Welcome to…

FB

Facebook

$165.22

3.63 (2.25%)

SPOT

Spotify

$144.16

2.565 (1.81%)

AAPL

Apple

$188.13

1.56 (0.84%)

SNAP

Snap

$10.93

0.3 (2.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 27

    Mar

  • 03

    Apr

  • 04

    Apr

WTW

WW

$19.50

-0.34 (-1.71%)

15:50
03/20/19
03/20
15:50
03/20/19
15:50
Conference/Events
WW management to meet with Oppenheimer »

Meeting to be held New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

  • 28

    May

WMT

Walmart

$98.64

-1.25 (-1.25%)

15:49
03/20/19
03/20
15:49
03/20/19
15:49
Periodicals
Breaking Periodicals news story on Walmart »

Walmart CTO leaving…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    May

WIFI

Boingo Wireless

$20.68

-0.25 (-1.19%)

15:41
03/20/19
03/20
15:41
03/20/19
15:41
Conference/Events
Boingo Wireless management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 26

    Mar

  • 27

    Mar

  • 28

    Mar

  • 29

    Mar

  • 28

    May

C

Citi

$65.04

-0.59 (-0.90%)

15:40
03/20/19
03/20
15:40
03/20/19
15:40
Periodicals
Citi plans to sell Venezuelan gold placed as collateral, Reuters says »

Citigroup intends to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Apr

  • 16

    Apr

  • 28

    May

  • 13

    Jul

EVER

EverQuote

$7.70

(0.00%)

15:40
03/20/19
03/20
15:40
03/20/19
15:40
Conference/Events
EverQuote management to meet with Oppenheimer »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 28

    Mar

CASY

Casey's General Stores

$127.10

0.55 (0.43%)

15:40
03/20/19
03/20
15:40
03/20/19
15:40
Options
Call spreads and put spreads in Caseys General Stores »

Call spreads and put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Apr

  • 03

    Apr

LRAD

LRAD Corporation

$2.82

-0.03 (-1.05%)

15:39
03/20/19
03/20
15:39
03/20/19
15:39
Conference/Events
LRAD Corporation management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 26

    Mar

KAMN

Kaman

$57.82

0.325 (0.57%)

15:38
03/20/19
03/20
15:38
03/20/19
15:38
Periodicals
Kaman exploring sale of distribution segment, Bloomberg says »

The company's KDG…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Apr

PVTL

Pivotal Software

$19.94

-0.02 (-0.10%)

15:36
03/20/19
03/20
15:36
03/20/19
15:36
Options
Calls lead puts 25:1 in Pivotal Software »

Calls lead puts 25:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Mar

SYX

Systemax

$21.53

0.23 (1.08%)

15:35
03/20/19
03/20
15:35
03/20/19
15:35
Conference/Events
Systemax management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 28

    Mar

WSM

Williams-Sonoma

$57.40

0.61 (1.07%)

15:34
03/20/19
03/20
15:34
03/20/19
15:34
Options
Williams Sonoma options imply 10.5% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 02

    Apr

  • 03

    Apr

SCS

Steelcase

$15.43

-2.055 (-11.75%)

15:34
03/20/19
03/20
15:34
03/20/19
15:34
Conference/Events
Steelcase management to meet with Sidoti »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Mar

  • 25

    Mar

  • 14

    May

  • 24

    Jun

  • 26

    Jun

15:30
03/20/19
03/20
15:30
03/20/19
15:30
General news
Powell on the maturity distribution of the portfolio: »

Powell on the maturity…

VLKAY

Volkswagen

$0.00

(0.00%)

15:25
03/20/19
03/20
15:25
03/20/19
15:25
Periodicals
Volkswagen management not yet aligned on restructuring plans, Reuters says »

Volkswagen's board…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:20
03/20/19
03/20
15:20
03/20/19
15:20
General news
Powell on the balance sheet: »

Powell on the balance…

15:20
03/20/19
03/20
15:20
03/20/19
15:20
General news
Powell on Brexit »

Powell on Brexit: he hope…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.